You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

ACEI or ARB Therapy for Left Ventricular Systolic Dysfunction-HF Patients

Percent of HF patients with LVSD who are prescribed an ACEI or ARB at hospital discharge. For purposes of this measure, LVSD is defined as chart documentation of a LVEF less than 40% or a narrative description of left ventricular systolic function consistent with moderate or severe systolic dysfunction.

Date Reviewed: November 7, 2015

Measure Info

NQF 0162NQF Endorsement Removed
Measure Type: 
Process
Measure Steward: 
Centers for Medicare and Medicaid Services
Clinical Topic Area: 
Heart Failure

Care Setting: 
Inpatient
Data Source: 
Claims
Paper Medical Records

ACP supports this measure. The balance of evidence shows that long-term treatment with beta blockers and angiotensin converting enzyme inhibitors can lessen the symptoms of heart failure, improve the clinical status of patients and enhance the patient's overall sense of well-being. The measure aligns with current guidelines and represents high-value care.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!